Latest News
& Press Releases
Browse the latest news from BioSpace, and press releases from around the industry. Want to filter by date, keyword, and more? Search here.
TOP STORIES
The FDA approved the latest indication for Rinvoq (upadacitinib) based on data from two Phase III studies, SELECT-PsA 1 and SELECT-PsA 2.
Although it’s not yet clear how dangerous the Omicron variant of COVID-19 actually is, it clearly is very infectious and rates are rising in the U.S. and around the world.
These results set Lilly up well to submit a Biologics License Application (BLA) in the first half of 2022.
The latest warning letter asks Medtronic to update its systems and procedures in order to deliver safe and high-quality devices to consumers.
Mythic Therapeutics has roared out of the gate with a $103 million Series B financing round that will support “safer and smarter” next generation of antibody-drug conjugates (ADCs).
Many big companies, including Amgen, Moderna, Roche and Novartis, had already decided not to attend in-person and the sentiment was leaning that way.
The FDA’s approval of Xeljanz is based on Pfizer’s Phase III multicenter, double-blind, placebo-controlled study. Here are more details about the study.
During a season of giving, investors were extra generous to these biotech companies this week.
A member of BioSpace’s Class of 2021, CODA aims to modify neuronal cell populations using gene therapy to express a tunable ligand-gated ion channel.
The JP Morgan Health Care Conference is held annually in January, and usually kicks off the biggest biopharma business news stories of the year. But in 2022, it’ll do so without at least three big names in the industry.
Good data management means developing a systematic way to integrate and update data enterprise-wide and to share it with team members or partners as needed.
Bristol Myers Squibb is dropping $920 million to acquire the exclusive global rights of Immatics’ experimental cancer drug program, the companies announced Tuesday morning.